Patients with thrombocytopenia are at an increased risk of both bleeding and ischemic events following PCI; however, there is a paucity of data on how to optimally manage these risks. Data indicates that ticagrelor is associated with reduced ischemic outcomes with an accompanying increased risk of bleed in the broader population. This study will assess P2Y12 agent selection in patients with chronic thrombocytopenia to determine if one better balances risks of ischemic and bleeding events following coronary intervention
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥ 18 years
PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
Thrombocytopenia defined as platelet count \<100 x103 /µL on at least one occasion prior to PCI
At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor
You may not be if
Death within 48 hours post-PCI
DAPT prior to cardiac catheterization
Clareo Health | Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia
